The EpiPen Debacle Is Just One Example of Drug Companies Run Amuck

0

Are you or someone you know allergic to peanuts or its derivatives, bee stings or other substances that could endanger your life if exposed to it?

If the answer is yes, you are probably fuming that the actions of a big drug company could be putting you or someone you know in danger.

If you are one of the thousands of people who have too purchase and keep an EpiPen close at hand to administer that acute allergen epinephrine as a life saving measure, to ensure you or others don’t go into anaphylactic shock, then you are probably aware or have already experienced the

sticker shock from the recent huge price increase imposed by the drug’s producer, Mylan Pharmaceuticals.

The company recently raised the price of a two-pack of needles to over $600, a steep 500% increase over what it cost in 2007. And they did it not for reasons of scarcity or increases in the cost of ingredients, but according to Mylan’s CEO, because it’s just what the company calculated it could charge more for one of its leading products. In other words, they did it because they can.

Public outrage and pressure from elected officials has prompted the company to distribute 700,000 free EpiPens to more than 65,000 schools across the country. The company is also looking to sell a less expensive generic version of the product.

On Wednesday it was reported that the New York attorney general has initiated an investigation to determine if Mylan has engaged in anti-competitive practices in regards to the EpiPen.

That’s an important step, but it doesn’t address the larger problem, namely that Mylan isn’t the only pharmaceutical company to hike up the price of its products to outlandish amounts because they know they can get away with it.

Now, if the public expects things to change, they will have to place pressure on the federal bureaucracy that’s supposed to regulate the industry, and demand that their elected representatives in Washington D.C. get the backbone needed to challenge unscrupulous practices in the pharmaceutical industry.

Only the public can give Congress the guts it needs to stand up to the pharmaceutical industry’s deep-pocketed lobbyists, who have so far done a great job of paralyzing those who could enact regulations to ensure that drug manufacturers earn decent return on their investments, but not an outrageous amount that will bankrupt every American.

Since Americans have been sold a bill of goods about how nationalizing health care is socialized medicine, even though all other industrialized democracies have adopted this model to great success, Americans must demand that their elected officials represent the interest of every day people, and if they don’t, threaten to defeat every member of Congress who votes against legislation to control the cost of health care in the country.

Posted - Copyright © 2022 Eastern Group Publications, Inc.

Share.
Print This Post Print This Post

Leave A Reply

Comments are intended to further discussion on the article topic. EGPNews reserves the right to not publish, edit or remove comments that contain vulgarities, foul language, personal attacks, racists, sexist, homophobic or other offensive terminology or that contain solicitations, spam, or that threaten harm of any sort. EGPNews will not approve comments that call for or applaud the death, injury or illness of any person, regardless of their public status. Questions regarding this policy should be e-mailed to service@egpnews.com.